This article has no abstract; the first 100 words appear below.
Despite the extraordinary advances in treating human immunodeficiency virus (HIV) infection during the past two decades, mortality, especially in resource-limited areas, remains unacceptably high. The leading killer of persons with HIV infection in these areas is tuberculosis, which accounted for more than a quarter of a million deaths in 2018.1 Among persons with low CD4+ T-cell counts who start antiretroviral therapy (ART) in low- and middle-income countries, the risk of tuberculosis developing within 6 months after starting therapy is as high as 20%, which exacts a heavy burden in terms of suffering and death. Diagnosing tuberculosis in such patients is . . .